Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

547
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
547
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
Aneurysm II: Clinical Manifestations and Diagnostic Studies01:21

Aneurysm II: Clinical Manifestations and Diagnostic Studies

386
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
386
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

614
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
614
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

354
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
354
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Holistic Health Approaches for People With Alcohol Use Disorder: Protocol for a Scoping Review.

JMIR research protocols·2026
Same author

Association of GLP-1 Receptor Agonist Prescriptions and Alcohol Consumption in the National Institutes of Health's All of Us Cohort.

Alcohol, clinical & experimental research·2026
Same author

Leveraging barbershops for community-based addiction research: A pilot study using hair samples to detect fentanyl and stress biomarkers.

Journal of substance use and addiction treatment·2026
Same author

A Secondary, Subgroup Analysis of Alcohol Cue-Exposure Craving in Response to Pharmacological Inhibition of the Growth Hormone Secretagogue Receptor With PF-5190457.

Alcohol, clinical & experimental research·2026
Same author

Predicting Outpatient Follow-Up Retention After Inpatient Treatment in Patients With Alcohol Use Disorder: A Data-Driven Random Forest Approach.

Addiction biology·2026
Same author

Holistic Health Approaches for People with Alcohol Use Disorder: Protocol for a Scoping Review.

JMIR research protocols·2026

Related Experiment Video

Updated: Feb 16, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.5K

Advances in Pharmacotherapy Development: Human Clinical Studies.

Raye Z Litten1, Daniel E Falk2, Megan L Ryan2

  • 1Division of Medications Development, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA. rlitten@mail.nih.gov.

Handbook of Experimental Pharmacology
|January 3, 2018
PubMed
Summary

New medications for alcohol use disorder (AUD) are in development, aiming for greater efficacy than current treatments. Research focuses on identifying the most effective and safe options for patients with AUD.

Keywords:
Alcohol use disorderHuman studiesMedications developmentPharmacotherapy

More Related Videos

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.7K
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
08:14

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Published on: March 22, 2024

2.0K

Related Experiment Videos

Last Updated: Feb 16, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.5K
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

8.7K
Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research
08:14

Author Spotlight: Developing Innovative Therapeutic Strategies for Hemorrhagic Shock Research

Published on: March 22, 2024

2.0K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Public Health

Background:

  • Current medications for alcohol use disorder (AUD) have limited efficacy.
  • Approved AUD medications include disulfiram, naltrexone, acamprosate, and nalmefene.

Purpose of the Study:

  • To review the efficacy and safety of novel AUD medications in human trials.
  • To discuss ongoing research for new AUD treatment compounds.

Main Methods:

  • Review of human studies on emerging AUD medications.
  • Analysis of pharmacologic targets for AUD treatment.

Main Results:

  • Several new medications targeting various pathways are under investigation.
  • Current treatments offer modest benefits for a limited patient subset.

Conclusions:

  • Developing more effective and safer AUD medications is a priority.
  • Identifying patient subgroups who will benefit most is crucial for improving treatment outcomes and public health.